The funding and pipeline data you need to inform decisions

The latest G-FINDER 2024 Landscape of Emerging Infectious Disease R&D: Lessons Learned report

Examining what we've learnt from a decade of epidemics, this report asks what the impact has been from all the R&D funding into emerging infectious diseases since the West African Ebola epidemic of 2014.

G-FINDER 2023 Neglected Disease Research & Development report: The Higher Cost of Lower Funding

Covering the changes in neglected disease funding in 2022 and, for the first time, adding comprehensive coverage of the product pipeline in each disease area.

G-FINDER 2023 Sexual & Reproductive Health Research & Development report: Beyond Spillovers

Funding for the range of sexual and reproductive health issues included in this report has grown by nearly $200m since we began collecting data in 2018; an increase of nearly 50%. But this growth has not been distributed equally - investment in maternal health has languished.

G-FINDER 2022 Neglected Disease Research & Development report: The Status Quo Won't Get Us There

Funding for neglected tropical diseases has been stagnating for more than a decade. This report asserts that we need a new model for attracting R&D funding, as the existing approach consistently fails to deliver investment at the scale required.

Infectious Disease R&D Tracker

The Infectious Disease R&D pipeline tracker covers approved products and technologies, as well as candidates in the development pipeline, for global health priorities.

Maternal Health Pipeline

Created with the aim of accelerating innovation, this pipeline tracks the critical medicines, diagnostics and drugs approved and in the development pipeline for the most significant pregnancy-related conditions.

Snakebite Envenoming Medicines Database

The most up-to-date view of snakebite envenoming medicines investigated or approved since 2015..